4 recruiting, 1 active not recruiting, 1 unknown. 2 Phase 1, 2 Phase 2, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 2 | Recruiting 2 |
| Early Phase 1 | 1 | Unknown 1 |
Follow (225)Ac-PSMA-617: new trials by email Literature Review of (225)Ac-PSMA-617 trials Research Report on (225)Ac-PSMA-617
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide - Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 107 | 2025-12-12 | 2026-09-17 |
| Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy - Prostate Cancer, Prostate Cancer (Diagnosis) | Phase 1 | Recruiting | Thomas Hope | 45 | 2025-07-08 | 2026-08-28 |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC AAA817, ARPI, Standard of Care - Prostate Cancer | Phase 3 | Recruiting | Novartis Pharmaceuticals | 940 | 2025-07-01 | 2026-10-15 |
| Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy Investigators choice of SoC, AAA817 - Prostate Cancer | Phase 2 / Phase 3 | Recruiting | Novartis Pharmaceuticals | 443 | 2025-02-27 | 2026-09-22 |
| Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer 225^Ac-PSMA-617, 68^Ga-PSMA-11 - Prostatic Neoplasms, Castration-Resistant | Phase 1 | Active not recruiting | Endocyte | 101 | 2021-04-01 | 2026-04-30 |
| Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer 225Ac-PSMA - Metastatic Castration-resistant Prostate Cancer | Early Phase 1 | Unknown | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 20 | 2020-01-01 | 2020-01-13 |
Prostatic Neoplasms (4) · Disease (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Diseases (1) · Prostatic Neoplasms, Castration-Resistant (1) · Urogenital Neoplasms (1)
Novartis Pharmaceuticals (2) · Endocyte (1) · Jonsson Comprehensive Cancer Center (1) · Thomas Hope (1) · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (1)
United States (4) · Australia (3) · Brazil (2) · China (2) · Hong Kong (2) · Japan (2) · Mexico (2) · Singapore (2) · South Korea (2) · Taiwan (2) · India (1) · Israel (1) · Malaysia (1) · South Africa (1) · Switzerland (1)
Amar Kishan (1) · Thomas A Hope, MD (1)